Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
about
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsGenetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.
P2860
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@ast
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@en
type
label
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@ast
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@en
prefLabel
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@ast
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@en
P2093
P2860
P1433
P1476
Phase 1 trial of carfilzomib ( ...... or refractory B-cell lymphomas
@en
P2093
April D Rollins
Beata Holkova
Caryn Weir-Wiggins
Changyong Feng
Derick R Peterson
Ellen Shrader
Emily Pierce
Erin M Cebula
Heidi Sankala
Jonathan W Friedberg
P2860
P304
P356
10.3109/10428194.2015.1075019
P577
2015-10-12T00:00:00Z